Furthermore, the TH-MYCN and ALKF1174L transgenic mouse models have a low incidence of bone metastases (205, 206), suggesting that tumors from patients with high-risk neuroblastoma, in whom bone metastases are common, may be different from those that develop in these transgenic models. Here, MYCN is linked to neuroblastoma.